Kalkine has a fully transformed New Avatar.

ICU Medical Inc

Healthcare US ICUI

132.41USD
-0.93(0.70%)

Last update at 2026-03-10T20:00:00Z

Day Range

129.98134.88
LowHigh

52 Week Range

78.28196.57
LowHigh

Fundamentals

  • Previous Close 133.34
  • Market Cap2555.99M
  • Volume228747
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA262.43M
  • Revenue TTM2257.13M
  • Revenue Per Share TTM93.49
  • Gross Profit TTM 697.76M
  • Diluted EPS TTM-2.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -114.40900M 123.19M 97.49M 114.71M 22.37M
Minority interest - - - - -
Net income -74.28600M 103.14M 86.87M 101.03M 28.79M
Selling general administrative 608.35M 302.58M 283.95M 276.98M 328.15M
Selling and marketing expenses - - - - -
Gross profit 697.76M 491.49M 461.50M 471.86M 570.03M
Reconciled depreciation 235.15M 89.70M 94.85M 85.21M 74.73M
Ebit -8.70400M 52.38M 41.81M 63.22M 115.75M
Ebitda 226.45M 142.08M 136.66M 148.43M 190.49M
Depreciation and amortization 235.15M 89.70M 94.85M 85.21M 74.73M
Non operating income net other - 0.80M 1.08M 7.90M 1.47M
Operating income -8.70400M 52.38M 41.81M 63.22M 21.61M
Other operating expenses 2283.57M 1175.03M 1135.43M 1125.67M 1211.03M
Interest expense 66.38M 0.86M 1.75M 0.55M 0.71M
Tax provision -40.12300M 20.05M 10.62M 13.67M -6.41900M
Interest income 4.43M - - 6.25M 3.41M
Net interest income -66.37500M -0.85800M -1.75300M -0.54900M -0.70900M
Extraordinary items - - - - -0.82600M
Non recurring - - - - -
Other items - - - - -
Income tax expense -40.12300M 20.05M 10.62M 13.67M -6.41900M
Total revenue 2280.00M 1316.31M 1271.00M 1266.21M 1400.04M
Total operating expenses 701.33M 350.21M 325.93M 331.33M 381.01M
Cost of revenue 1582.24M 824.82M 809.51M 794.34M 830.01M
Total other income expense net -105.70500M 70.80M 55.69M 51.49M -165.93200M
Discontinued operations - - - - -
Net income from continuing ops -74.28600M 103.14M 86.87M 101.03M 28.79M
Net income applicable to common shares -74.28600M 103.14M 86.87M 101.03M 28.79M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4378.44M 4515.64M 1880.74M 1763.69M 1692.38M
Intangible assets 870.59M 982.77M 188.31M 197.23M 211.41M
Earning assets - - - - -
Other current assets 91.21M 88.93M 2.23M 1.82M 4.36M
Total liab 2255.03M 2425.71M 264.71M 261.43M 315.14M
Total stockholder equity 2123.41M 2089.93M 1616.03M 1502.27M 1377.24M
Deferred long term liab - 5.16M 1.49M 1.66M 2.09M
Other current liab 228.15M 218.13M 97.99M 109.32M 105.78M
Common stock 2.41M 2.40M 2.13M 2.11M 2.07M
Capital stock 2.41M 2.40M 2.13M 2.11M 2.07M
Retained earnings 807.85M 837.50M 911.79M 808.65M 721.78M
Other liab - 244.71M 22.10M 18.10M 37.77M
Good will 1472.45M 1449.26M 43.44M 33.00M 31.25M
Other assets - 104.40M 106.35M 146.05M 76.98M
Cash 254.22M 208.78M 552.83M 396.10M 268.67M
Cash and equivalents - - - - -
Total current liabilities 481.84M 494.56M 200.78M 195.49M 248.47M
Current deferred revenue 31.64M 30.84M 12.65M 5.57M 6.70M
Net debt 1450.49M 1444.58M -507.78000M -343.95000M -232.41200M
Short term debt 72.02M 29.69M 9.01M 8.74M 7.36M
Short long term debt 51.00M 29.69M - - -
Short long term debt total 1704.72M 1653.36M 45.05M 52.15M 36.26M
Other stockholder equity 1366.23M 1331.01M 721.38M 693.03M 668.79M
Property plant equipment - 713.58M 468.37M 466.63M 456.08M
Total current assets 1219.60M 1235.20M 1029.81M 920.78M 882.20M
Long term investments 3.12M 3.69M 4.62M 12.97M 0.00000M
Net tangible assets - -342.09600M 1616.03M 1272.03M 1151.89M
Short term investments 0.50M 4.22M 14.42M 14.69M 23.97M
Net receivables 164.31M 221.72M 105.89M 124.09M 202.22M
Long term debt 1577.77M 1623.67M - - -
Inventory 709.36M 696.01M 290.24M 314.93M 337.64M
Accounts payable 150.03M 215.90M 81.13M 71.86M 128.63M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -53.08100M -80.97800M -19.26900M -1.52200M -15.40200M
Additional paid in capital - - - - -
Common stock total equity - - 2.13M 2.11M 2.07M
Preferred stock total equity - - - - -
Retained earnings total equity - - 911.79M 808.65M 721.78M
Treasury stock - - -0.02700M -0.03900M -0.15700M
Accumulated amortization - - - - -
Non currrent assets other 56.39M 105.46M 63.74M 55.48M 48.98M
Deferred long term asset charges - - - - 28.00M
Non current assets total 3158.84M 3280.45M 850.93M 842.91M 810.18M
Capital lease obligations 75.09M 80.94M 45.05M 52.15M 36.26M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1909.46800M 4.72M -3.92500M 15.25M -15.05600M
Change to liabilities 37.47M 9.48M -93.83100M -41.70600M -26.28000M
Total cashflows from investing activities -1909.46800M -90.68700M -98.13900M -166.88800M -103.37000M
Net borrowings 1641.31M -0.60700M -0.35700M -0.35700M -0.35700M
Total cash from financing activities 1637.03M -16.87000M -0.04000M -10.90700M 8.02M
Change to operating activities -54.22100M -22.75200M -49.75900M -64.93800M 62.52M
Net income -74.28600M 103.14M 86.87M 101.03M 28.79M
Change in cash -344.04300M 156.73M 127.43M -76.11100M 54.71M
Begin period cash flow 552.83M 396.10M 268.67M 344.78M 290.07M
End period cash flow 208.78M 552.83M 396.10M 268.67M 344.78M
Total cash from operating activities -62.12900M 267.54M 222.75M 101.92M 160.22M
Issuance of capital stock - - - - -
Depreciation 235.15M 89.70M 94.85M 85.21M 74.73M
Other cashflows from investing activities - -26.86100M -2.20900M -84.82800M 4.41M
Dividends paid - - - - -
Change to inventory -201.09500M 20.82M 19.20M -24.99700M -21.77000M
Change to account receivables -19.15100M 13.76M 78.05M -23.68400M -76.74200M
Sale purchase of stock - 1.04M 0.32M -18.63900M -6.25200M
Other cashflows from financing activities 1651.30M -16.26300M 150.32M 7.73M 14.28M
Change to netincome 73.76M 36.13M 46.29M 2.58M 68.50M
Capital expenditures 99.33M 81.17M 100.39M 106.04M 100.78M
Change receivables - 13.76M 78.05M -23.68400M 20.70M
Cash flows other operating - -6.37100M 0.03M 11.35M 14.91M
Exchange rate changes - -3.25100M 2.85M -0.23400M -10.15900M
Cash and cash equivalents changes - 156.73M 127.43M -76.11100M 54.71M
Change in working capital -303.72900M 15.04M -16.96600M -111.63600M -25.40600M
Stock based compensation 36.02M 27.34M 23.95M 21.92M 24.24M
Other non cash items 44.71M 29.50M 30.27M -22.22900M 37.58M
Free cash flow -161.45800M 186.37M 122.36M -4.12200M 59.44M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ICUI
ICU Medical Inc
-0.93 0.70% 132.41 - 20.70 1.06 1.13 1.70 15.18
ISRG
Intuitive Surgical Inc
-7.71 1.56% 485.85 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
-0.25 0.20% 122.50 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
4.90 2.00% 249.71 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
-1.58 0.95% 163.88 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

Profile

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

ICU Medical Inc

951 Calle Amanecer, San Clemente, CA, United States, 92673

Key Executives

Name Title Year Born
Mr. Vivek Jain CEO & Chairman 1972
Mr. Brian Michael Bonnell CFO & Treasurer 1974
Mr. Christian B. Voigtlander Chief Operating Officer 1969
Ms. Virginia Ruth Sanzone Corp. VP, Gen. Counsel, Sec. & Compliance Officer 1975
Mr. Vivek Jain CEO & Chairman of the Board 1972
Mr. Christian B. Voigtlander Chief Operating Officer 1968
Ms. Virginia Ruth Sanzone Corporate VP, General Counsel, Secretary & Compliance Officer 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.